Anixa Biosciences announced that the FDA has cleared the Investigational New Drug (IND) application for its breast cancer vaccine. The technology immunizes against the alpha-lactalbumin protein that is expressed in the mammary glands of women during lactation. After lactation, the protein is no longer expressed until a woman develops breast cancer. Researchers anticipate that the vaccine will support the immune system in destroying cancer cells before they have the opportunity to grow into a mature cancer. Yourway is looking forward to seeing the results of further trials and fully supports the fight against cancer.